Clinical trial · Interventional
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
NCT03930953CI-TRIAL-00103639active not recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CC-99282 | Drug | — | UNRESOLVED |
| Obinutuzumab | Drug | Obinutuzumab | ALIAS |
| Rituximab | Drug | Rituximab | ALIAS |
| Tafasitamab | Drug | Tafasitamab | ALIAS |
| Valemetostat | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Part A: Dose Escalation
- interventionNames
- Drug: CC-99282
- type
- EXPERIMENTAL
- label
- Part B: Dose Expansion
- interventionNames
- Drug: CC-99282
- Drug: Rituximab
- Drug: Obinutuzumab
- Drug: Tafasitamab
- Drug: Valemetostat
Primary outcomes (9)
- measure
- Incidence of Adverse Events (AEs)
- timeFrame
- From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. Exclusion Criteria * Life expectancy ≤ 2 months. * Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter. * Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD). * Impaired cardiac function or clinically significant cardiac disease. * Other protocol-defined inclusion/exclusion criteria apply.
References
Publications (1)
- DERIVEDDuell J, Westin J. The future of immunotherapy for diffuse large B-cell lymphoma. Int J Cancer. 2025 Jan 15;156(2):251-261. doi: 10.1002/ijc.35156. Epub 2024 Sep 25. PMID 39319495